![]() |
ImmunoGen, Inc. Announces Start Of SAR566658 Clinical Testing
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, announced the start of clinical testing with SAR566658...
More... |
| All times are GMT -7. The time now is 04:05 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021